Quantcast

Latest Avastin Stories

8ebce1b9386aa8f5713297d017f504641
2009-07-30 09:30:00

UCLA researchers have uncovered a new way to scan brain tumors and predict which ones will be shrunk by the drug Avastin -- before the patient ever starts treatment. By linking high water movement in tumors to positive drug response, the UCLA team predicted with 70 percent accuracy which patients' tumors were the least likely to grow six months after therapy.Bronnie McNabb, 57, considers himself lucky. When his aggressive brain cancer returned after chemotherapy and radiation, his UCLA doctor...

e3ee029267b363ee362c969a267b606c1
2009-05-31 09:25:00

The mixture of two anti-cancer medications, along with chemotherapy, can gradually halt advanced non-small cell lung cancer, says a new study released on Saturday. Patients given Tarceva, made by the Swiss manufacturer Roche, and Avastin, saw their cancer growth halt more than a different group given just Avastin. 750 patients were randomly selected and given either Avastin and a placebo, or Avastin and Tarceva. The Tarceva group lived about 4.8 months before the cancer grew again,...

2009-05-11 09:32:06

The U.S. Food and Drug Administration has approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme -- a form of brain cancer. GBM is a rapidly progressing cancer that invades brain tissue and can impact physical activities and mental abilities, the FDA said. It affects about 6,700 persons in the United States every year. Following initial treatment with surgery, radiation, and/or chemotherapy, the cancer nearly always returns, the agency said. This type of cancer is very...

2009-04-22 22:22:36

The drug Avastin fell short in a clinical trial of its goal to reduce the recurrence of early-stage colon cancer, U.S. drug maker Genentech says. The Phase III study, which looked at the effectiveness of chemotherapy combined with Avastin on patients with Stage II or III colon cancer, was conducted by the National Surgical Adjuvant Breast and Bowel Project, Genentech said Tuesday. The drug maker said Avastin failed to meet its targeted numbers in the trial but an initial review of the study...

2009-04-22 07:00:00

Sutent/Taxol Will Earn Decision Resources' Clinical Gold Standard Status for the Indication by 2012, According to a New Report from Decision Resources WALTHAM, Mass., April 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the attribute that most influences their prescribing decisions in metastatic triple-negative breast...

2009-04-08 07:00:00

Although Market Growth Will be Robust, Drug Development Has Been Disappointing in Recent Years, According to a New Report from Decision Resources WALTHAM, Mass., April 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the small-cell lung cancer drug market will more than double from just under $250 million in 2007 to more than $684 million in 2017, owing to the launches of Genentech/Roche/Chugai's...

2009-04-07 15:39:26

A U.S. study indicates the use of the drug Avastin to treat a subgroup of recurrent brain tumors is safe and effective at delaying tumor progression. The retrospective study conducted at the Seattle Cancer Care Alliance involved 22 patients suffering from a recurrent malignant glioma known as alkylator-refractory anaplastic oligodendroglioma, for which there is no existing standard therapy. Avastin, known generically as bevacizumab, is the first approved therapy designed to inhibit...

2009-03-31 22:50:04

A U.S. Food and Drug Administration committee is recommending accelerated approval of the drug Avastin for treating brain cancer. Drug maker Genentech Inc. said the FDA is expected to make a decision next month on use of the colon cancer drug in patients with previously treated glioblastoma, the most aggressive form of brain cancer. The application is based on positive, independently reviewed data from a Phase II study of brain cancer patients. The study found that 43 percent of patients...

2009-03-11 07:45:00

Unmet Need for Efficacious Therapies for Treating Patients With Mutated KRAS Genes Presents Significant Opportunity for Drug Developers, According to a New Report from Decision Resources WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches of Roche/Genentech/Chugai's Avastin and Bristol-Myers Squibb/ImClone Systems*/Merck KGaA's Erbitux will drive the colorectal...

2009-03-10 07:00:00

However, Off-Label Use of Avastin Will Take Market Share Away from Lucentis from 2012 to 2017, According to a New Report from Decision Resources WALTHAM, Mass., March 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that robust annual 17 percent growth in the age-related macular degeneration (AMD) market through 2012 will be driven primarily by expanding use of Genentech/Novartis Ophthalmics'...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.